Maria Palasis, the President & CEO of $LYRA, sold 1,565 shares of the company on 07-10-2025 for an estimated $13,944. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.1% of their shares of this class of stock. Following this trade, they now own 1,098,435 shares of this class of $LYRA stock.
$LYRA Insider Trading Activity
$LYRA insiders have traded $LYRA stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $LYRA stock by insiders over the last 6 months:
- MARIA PALASIS (President & CEO) sold 1,565 shares for an estimated $13,944
- JASON CAVALIER (Chief Financial Officer) sold 684 shares for an estimated $6,094
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LYRA Hedge Fund Activity
We have seen 20 institutional investors add shares of $LYRA stock to their portfolio, and 23 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SAMSARA BIOCAPITAL, LLC removed 575,559 shares (-29.3%) from their portfolio in Q1 2025, for an estimated $72,693
- QUBE RESEARCH & TECHNOLOGIES LTD removed 342,159 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $43,214
- GOLDMAN SACHS GROUP INC removed 185,314 shares (-33.4%) from their portfolio in Q1 2025, for an estimated $23,405
- MORGAN STANLEY removed 150,866 shares (-69.7%) from their portfolio in Q1 2025, for an estimated $19,054
- GEODE CAPITAL MANAGEMENT, LLC added 130,038 shares (+14.7%) to their portfolio in Q1 2025, for an estimated $16,423
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 114,137 shares (+110.4%) to their portfolio in Q1 2025, for an estimated $14,415
- JPMORGAN CHASE & CO removed 100,165 shares (-64.0%) from their portfolio in Q1 2025, for an estimated $12,650
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
